hotspot -WSS

hotspot

author：comprehensive 2025-10-02 19:39:02 - browse：67575

Transparent plastic divider on the reception desk in the hospital admission department with red lettering emergency. — Adobe

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack.

The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

The device maker, which also sells products like the QuickVue Covid-19 antigen test, sent letters to health systems in May telling them to immediately stop using the test. The Food and Drug Administration classified the recall as serious, because problems with the product could result in serious injury or death. QuidelOrtho has reported 41 complaints, but no injuries or deaths so far.

The tests, which use either a blood or plasma sample, promise to return results in under half an hour. They are used in emergency rooms to triage patients suspected of having a heart attack.

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

The FDA said the patients most at risk are those with zero or abnormal heart attack symptoms, for whom a diagnosis would be easy to miss without an accurate lab test.

The company advised using a different testing method to detect heart attacks. If none are available, doctors should be extra wary of the blood panel’s readings, perform multiple tests to confirm low troponin levels, and also reference data from EKGs and other imaging.

San Diego-based QuidelOrtho said the error is due to a “raw material issue” in its recall record. The issue caused the test to falsely pick up 30% less troponin than is present. The company did not respond to STAT’s request for more information on the error.

The test maker’s last serious recall was in 2021 for reports of false negatives from its Lyra PCR Covid-19 test when used with certain lab equipment. The notice impacted more than 18,000 test kits.

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： 2 officers injured in shooting in Orlando, police say

hotspot

WSS

Florida officials tell state schools to teach AP Psychology 'in its entirety'

Flint parents haunted by uncertainty, fears of lead poisoning

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

When waiting feels immoral: Empathy in the emergency department

In search for therapies for solid tumors, companies turn to claudin

Medicare slashes safety net hospital payments by nearly $1 billion

knowledge

hotspot

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Affirmative action in medical school literally saved lives

Personalized medicine goes far beyond genetics

Anesthesiologist group: stop taking Ozempic before surgery

FDA scientists endorse Pfizer/BioNTech Covid

State Dept. review finds Biden bears some blame for Afghanistan failures

The a glaring gap in research on serious mental illness and primary care

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Wikipedia

It costs an awful lot of money to give away a kidney

International team creates first chimeric human

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Covid isolation guidance eased by the CDC

'Null' research findings aren't empty of meaning. Let's publish them

FDA approves Sage Therapeutics’ rapid

hotspot

hotspot

explore

focus